<DOC>
	<DOCNO>NCT00121680</DOCNO>
	<brief_summary>The purpose study study safety E7080 administer patient solid tumor lymphomas . Please note : study recruit patient advanced and/or metastatic melanoma . In current phase study , To determine MTD pharmacokinetic profile E7080 give continuous daily ( qd ) dose combination temozolomide .</brief_summary>
	<brief_title>A Phase I/Ib , Multicenter , Open-Label , Dose Escalation Study E7080 Patients With Solid Tumors Combination With Temozolomide Patients With Advanced and/or Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>Patients histologically and/or cytologically confirm solid tumor lymphoma resistant/refractory approve therapy curative therapy available All previous treatment ( include surgery radiotherapy ) must complete least four week prior study entry acute toxicity must resolve Aged 18 year . Because potential additional risk child suggest preclinical model dysplasia grow epiphyseal growth plate , enrollment limit adult patient ECOG performance status score 0 1 Written inform consent prior study specific screen procedure understand patient may withdraw consent time without prejudice Willing able comply protocol guideline duration study For patient Schedule 2 Expanded Melanoma Cohort : histologically and/or cytologically confirm advanced and/or metastatic melanoma resistant/refractory approve therapy curative therapy available . In addition , patient must melanoma lesion amenable tissue biopsy must agree undergo biopsy malignant adjacent nonmalignant tissue pretreatment end Cycle 1 treatment For patient Melanoma Combination Cohort : histologically and/or cytologically confirm melanoma advance and/or metastatic Untreated unstable metastasis central nervous system ( CNS ) tumor . Patients complete local therapy discontinue use steroid indication least 4 week prior commence treatment stability proven least 2 CT MRI scan obtain least 4 week apart permit Any follow laboratory parameter : hemoglobin &lt; 9 g/dL ( 5.6 mmol/L ) ; neutrophil &lt; 1.5 x 109/L ; platelet &lt; 100 x 109/L ; serum bilirubin &gt; 25 mol/L ( 1.5 mg/dL ) ; liver function test value &gt; 3 x upper limit normal ( ULN ) ; renal function serum creatinine &gt; 1.5 ULN creatinine clearance &lt; 60 mL/min Positive history HIV , active hepatitis B active hepatitis C severe/uncontrolled intercurrent illness infection Patients centrally locate nonsmall cell lung cancer squamous cell lung cancer Clinically significant cardiac impairment unstable ischemic heart disease include myocardial infarction within six month study start Patients mark Baseline prolongation QT/QTc interval ( QTc interval &gt; 450 msec male &gt; 470 msec female ) use Fridericia method QTc analysis Bleeding thrombotic disorder , use therapeutic dosage anticoagulant , warfarin . Occasional use NSAIDs antiplatelet agent aspirin , clopidogrel , aggrenox dipyridamole consider exclusionary take &lt; 7 day per 28 day . However , patient require chronic use ( &gt; /=7 day 28 day ) full dose aspirin NSAIDs patient exclude . Concomitant antiplatelet agent NSAIDs use caution Requirement chronic use full dose aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) Poorly control hypertension ( define require change hypertensive regimen within 1 week three month study entry ) patient diagnose hypertension base repeat blood pressure measurement &gt; 160/90 mmHg Screening &gt; 1+ proteinuria urine dipstick test 30 mg/dL A history gastrointestinal malabsorption undergone surgery require gastrointestinal anastomosis within four week start therapy recover major surgery within three week start therapy History alcoholism , drug addiction , psychiatric psychological condition , opinion Investigator , would impair study compliance Any treatment investigational drug within 30 day start study Previous treatment E7080 Known intolerance temozolomide ( excipients ) Women pregnant breastfeeding ; woman childbearing potential positive pregnancy test Screening pregnancy test . Women childbearing potential unless ( 1 ) surgically sterile ( 2 ) use adequate measure contraception ( include two form contraception , one must barrier method ) opinion Investigator ( revise per Amendment 04 ) . Perimenopausal woman must amenorrheic least 12 month consider nonchildbearing potential Fertile male female partner willing use contraception whose female partner use adequate contraceptive protection Legal incapacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>cancer</keyword>
</DOC>